title: Prognostic value of peritoneal washing cytology in gynecologic malignancies: a controversial issue.
abstract: OBJECTIVE
  To evaluate the prognostic impact of peritoneal washing cytology in patients with endometrial and ovarian cancers.
  
  
  METHODS
  We retrospectively identified 86 individuals with ovarian carcinomas, ovarian borderline tumors and endometrial adenocarcinomas. The patients had been treated at Shahid Sadoughi Hospital and Ramazanzadeh Radiotherapy Center, Yazd, Iran between 2004 and 2012. Survival differences were determined by Kaplan-Meier analysis. Multivariate analysis was performed using the Cox regression method. A p<0.05 value was considered statistically significant.
  
  
  RESULTS
  There were 36 patients with ovarian carcinomas, 4 with borderline ovarian tumors and 46 with endometrial carcinomas. The mean age of the patients was 53.8±15.2 years. In patients with ovarian carcinoma the overall survival in the negative cytology group was better than the patients with positive cytology although this difference failed to reach statistical significance (p=0.30). At 0 to 50 months the overall survival was better in patients with endometrial adenocarcinoma and negative cytology than the patients with positive cytology but then it decreased (p=0.85). At 15 to 60 months patients with FIGO 2009 stage IA-II endometrial andocarcinoma and negative peritoneal cytology had a superior survival rate compared to 1988 IIIA and positive cytology only, although this difference failed to reach statistical significance(p=0.94). Multivariate analysis using Cox proportional hazards model showed that stage and peritoneal cytology were predictors of death.
  
  
  CONCLUSIONS
  Our results show good correlation of peritoneal cytology with prognosis in patients with ovarian carcinoma. In endometrial carcinoma it had prognostic importance. Additional research is warranted.
authors.affiliation: Department Of Pathology, Shahid Sadoughi University of Medical Sciences, Iran E-mail : ali52akhavan@yahoo.com.
authors.forename: Fariba
authors.initials: F
authors.lastname: Binesh
authors.forename: Ali
authors.initials: A
authors.lastname: Akhavan
authors.forename: Nasim
authors.initials: N
authors.lastname: Behniafard
authors.forename: Somayeh
authors.initials: S
authors.lastname: Zabihi
authors.forename: Elhamsadat
authors.initials: E
authors.lastname: Hosseinizadeh
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D016001:Confidence Intervals; D003581:Cytodiagnosis / Q000379:methods; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D007492:Iran; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D010533:Peritoneal Lavage / Q000379:methods*; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy